Programs
-
Biologics Characterization
Biopharmaceuticals can exhibit significant heterogeneity due to posttranslational modifications (PTMs) such as glycosylation, oxidation, deamidation, and phosphorylation, as well as structural modifications. Additionally, variations in upstream and downstream processes during the recombinant production of biologics can further influence structural heterogeneity. Therefore, comprehensive characterization of biologics is essential to ensure their safety and efficacy.
The Biologics Characterization Facility offers the following services:
Antibody-Drug Conjugate (ADC) analysis
Disulfide linkage analysis
Host Cell Proteins (HCP) analysis using Mass Spectrometry
Intact Mass (Reduced/Non-Reduced)
N-glycan Analysis
Peptide mapping
Post-translational modification analysis
Peptide-Drug Impurity Profiling
Peptide Quantification
Sequence variance analysis
Sialic Acid Quantitation
We are working towards making the Biologics Characterization Facility compliant with ISO standards -
HT Parekh Foundation Project - Last Mile Cold Chain Carrier for COVID-19 Vaccination in North East India
This project aims to utilize CSR funding from the HT Parekh Foundation to enhance COVID-19 vaccination efforts in remote regions of Manipur and Assam. Developed by Blackfrog Technologies, the initiative incorporates cutting-edge cold chain technology with user-friendly features to combat vaccine spoilage caused by thermal fluctuations typically seen in traditional iceboxes. SELCO Foundation will collaborate with C-CAMP for on-ground implementation, as the technology is solar-compatible. With easy portability and battery backup while maintaining strict WHO-recommended temperatures, this innovation will support COVID-19 vaccination efforts in 48 PHSCs and 2 PHCs across 5 districts in Manipur, and 10 PHCs across 5 districts in Assam, serving a population of over 7.32 lakh living in remote, hilly terrains.
-
CCAMP-InDx program
In response to the COVID-19 crisis in India, the Indigenisation of Diagnostics (InDx) program was launched in August 2020 under the guidance of the Principal Scientific Adviser to the Government of India. The program, through a public-private partnership, aimed to unite various stakeholders to ensure a steady supply of COVID-19 molecular diagnostics.
The initiative focused on building a robust supply chain network of Indian MSMEs, supporting them in meeting international quality standards and scaling up production to assemble one million indigenous diagnostic kits per day.
C-CAMP InDx developed a Digital Platform and established Centres of Excellence (CoEs) to further its mission. Funded by the Rockefeller Foundation, the program was executed by C-CAMP at the Bangalore Life Sciences Cluster (BLiSC) in collaboration with the CoEs.
Leadership Team
-
Dr. Taslimarif Saiyed
CEO and Director of C-CAMP
-
Prof. Satyajit Mayor
Co-founder
-
Mr. Shrikumar Suryanarayan
Demographics & Structure
-
Organisation Strength
None
Registration Details
-
CSR Form 1
Not Available
-
80G
AADCC8572DF20214
-
12A
AADCC8572DE20214
-
FCRA
Not Available
About
-
Headquarters
Bangalore, Karnataka
-
Since
2009
Impact
C-CAMP has supported over 350 startups and innovators across 34 states and union territories in India, investing up to Rs 80 crore and helping them raise Rs 2,000 crore at a cumulative valuation of over Rs 6,000 crore.
Vision and Mission
C-CAMP's mission is to be an enabler of cutting-edge life science research and innovation, with a vision to position India as a biotech innovation capital outside of the global north.
Political & Religious Declarations
-
Political Affiliation
-
Religious Affiliation
Location
-
Headquarters
Centre for Cellular and Molecular Platforms (C-CAMP) GKVK Post, Bellary Road, Bangalore 560 065, Karnataka, India
Directions, Bangalore, Karnataka -
Offices in Cities
Bangalore
Other Details
-
Type
Non-profit
-
Sub Type
Society
Website
Technology Adoption
-
SOC 2 Compliant
No
-
Financial Management
-
Beneficiary Management